Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the rights to the drug Byetta and newly approved Bydureon.
Popular Posts:
- Hospital CEO Takes on Health Care Reform
- Dendreon takes bigger 3Q loss, Provenge sales rise
- Hospital CEO Takes on Health Care Reform
- Analyst gauges financial loss from Novartis recall
- Health Insurance Reform: Secretary Sebelius Takes Your Questions …